Correlation between antibodies to type II collagen and treatment outcome in bilateral progressive sensorineural hearing loss

S. M. Helfgott, Carlos Lorenzo, R. Kieval, D. E. Trentham, Ra Mosciscki, J. San Martin, M. McKenna, J. Nadol

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Our aim was to assess whether "idiopathic" bilateral progressive sensorineural hearing loss (BPSHL) has an immunological cause in some patients; antibodies to native type II collagen were sought by an ELISA in eighteen patients with BPSHL, before and after corticosteroid treatment, and in twelve patients with Menière's disease, fifteen with otosclerosis, eighteen with rheumatoid arthritis, nine with fibrositis, and nine healthy controls. A positive result was defined as a mean dilution titre of 2 or more. Eight of eighteen BPSHL patients had positive titres-significantly (p<0·005) more than in any other group (one Menière's disease, two otosclerosis, and no others). The mean antibody titre was higher in the BPSHL group than in any other group (2·02 [SEM 0·62] vs 0·17 [0·17]) Menière's disease, 0·44 [0·32] otosclerosis, 0 all others; p<0·005). The nine BPSHL patients who showed a clinical response to corticosteroids (improvement in at least one tone by audiogram or 25 db in speech discrimination score) had the highest mean antibody titre (3·46 [0·88] vs 0·59 [0·59] for the nine non-responsive patients; p<0·04). We suggest that in some patients with BPSHL, immunity to type II collagen, a major constituent of the inner ear, may be important in the pathogenesis of the disorder.

Original languageEnglish (US)
Pages (from-to)387-389
Number of pages3
JournalThe Lancet
Volume337
Issue number8738
DOIs
StatePublished - Feb 16 1991
Externally publishedYes

Fingerprint

Collagen Type II
Sensorineural Hearing Loss
Antibodies
Otosclerosis
Adrenal Cortex Hormones
Speech Perception
Fibromyalgia
Inner Ear
Immunity
Rheumatoid Arthritis
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Helfgott, S. M., Lorenzo, C., Kieval, R., Trentham, D. E., Mosciscki, R., San Martin, J., ... Nadol, J. (1991). Correlation between antibodies to type II collagen and treatment outcome in bilateral progressive sensorineural hearing loss. The Lancet, 337(8738), 387-389. https://doi.org/10.1016/0140-6736(91)91165-Q

Correlation between antibodies to type II collagen and treatment outcome in bilateral progressive sensorineural hearing loss. / Helfgott, S. M.; Lorenzo, Carlos; Kieval, R.; Trentham, D. E.; Mosciscki, Ra; San Martin, J.; McKenna, M.; Nadol, J.

In: The Lancet, Vol. 337, No. 8738, 16.02.1991, p. 387-389.

Research output: Contribution to journalArticle

Helfgott, SM, Lorenzo, C, Kieval, R, Trentham, DE, Mosciscki, R, San Martin, J, McKenna, M & Nadol, J 1991, 'Correlation between antibodies to type II collagen and treatment outcome in bilateral progressive sensorineural hearing loss', The Lancet, vol. 337, no. 8738, pp. 387-389. https://doi.org/10.1016/0140-6736(91)91165-Q
Helfgott, S. M. ; Lorenzo, Carlos ; Kieval, R. ; Trentham, D. E. ; Mosciscki, Ra ; San Martin, J. ; McKenna, M. ; Nadol, J. / Correlation between antibodies to type II collagen and treatment outcome in bilateral progressive sensorineural hearing loss. In: The Lancet. 1991 ; Vol. 337, No. 8738. pp. 387-389.
@article{131dcbabbc5445c9ba80f39b485b64b0,
title = "Correlation between antibodies to type II collagen and treatment outcome in bilateral progressive sensorineural hearing loss",
abstract = "Our aim was to assess whether {"}idiopathic{"} bilateral progressive sensorineural hearing loss (BPSHL) has an immunological cause in some patients; antibodies to native type II collagen were sought by an ELISA in eighteen patients with BPSHL, before and after corticosteroid treatment, and in twelve patients with Meni{\`e}re's disease, fifteen with otosclerosis, eighteen with rheumatoid arthritis, nine with fibrositis, and nine healthy controls. A positive result was defined as a mean dilution titre of 2 or more. Eight of eighteen BPSHL patients had positive titres-significantly (p<0·005) more than in any other group (one Meni{\`e}re's disease, two otosclerosis, and no others). The mean antibody titre was higher in the BPSHL group than in any other group (2·02 [SEM 0·62] vs 0·17 [0·17]) Meni{\`e}re's disease, 0·44 [0·32] otosclerosis, 0 all others; p<0·005). The nine BPSHL patients who showed a clinical response to corticosteroids (improvement in at least one tone by audiogram or 25 db in speech discrimination score) had the highest mean antibody titre (3·46 [0·88] vs 0·59 [0·59] for the nine non-responsive patients; p<0·04). We suggest that in some patients with BPSHL, immunity to type II collagen, a major constituent of the inner ear, may be important in the pathogenesis of the disorder.",
author = "Helfgott, {S. M.} and Carlos Lorenzo and R. Kieval and Trentham, {D. E.} and Ra Mosciscki and {San Martin}, J. and M. McKenna and J. Nadol",
year = "1991",
month = "2",
day = "16",
doi = "10.1016/0140-6736(91)91165-Q",
language = "English (US)",
volume = "337",
pages = "387--389",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8738",

}

TY - JOUR

T1 - Correlation between antibodies to type II collagen and treatment outcome in bilateral progressive sensorineural hearing loss

AU - Helfgott, S. M.

AU - Lorenzo, Carlos

AU - Kieval, R.

AU - Trentham, D. E.

AU - Mosciscki, Ra

AU - San Martin, J.

AU - McKenna, M.

AU - Nadol, J.

PY - 1991/2/16

Y1 - 1991/2/16

N2 - Our aim was to assess whether "idiopathic" bilateral progressive sensorineural hearing loss (BPSHL) has an immunological cause in some patients; antibodies to native type II collagen were sought by an ELISA in eighteen patients with BPSHL, before and after corticosteroid treatment, and in twelve patients with Menière's disease, fifteen with otosclerosis, eighteen with rheumatoid arthritis, nine with fibrositis, and nine healthy controls. A positive result was defined as a mean dilution titre of 2 or more. Eight of eighteen BPSHL patients had positive titres-significantly (p<0·005) more than in any other group (one Menière's disease, two otosclerosis, and no others). The mean antibody titre was higher in the BPSHL group than in any other group (2·02 [SEM 0·62] vs 0·17 [0·17]) Menière's disease, 0·44 [0·32] otosclerosis, 0 all others; p<0·005). The nine BPSHL patients who showed a clinical response to corticosteroids (improvement in at least one tone by audiogram or 25 db in speech discrimination score) had the highest mean antibody titre (3·46 [0·88] vs 0·59 [0·59] for the nine non-responsive patients; p<0·04). We suggest that in some patients with BPSHL, immunity to type II collagen, a major constituent of the inner ear, may be important in the pathogenesis of the disorder.

AB - Our aim was to assess whether "idiopathic" bilateral progressive sensorineural hearing loss (BPSHL) has an immunological cause in some patients; antibodies to native type II collagen were sought by an ELISA in eighteen patients with BPSHL, before and after corticosteroid treatment, and in twelve patients with Menière's disease, fifteen with otosclerosis, eighteen with rheumatoid arthritis, nine with fibrositis, and nine healthy controls. A positive result was defined as a mean dilution titre of 2 or more. Eight of eighteen BPSHL patients had positive titres-significantly (p<0·005) more than in any other group (one Menière's disease, two otosclerosis, and no others). The mean antibody titre was higher in the BPSHL group than in any other group (2·02 [SEM 0·62] vs 0·17 [0·17]) Menière's disease, 0·44 [0·32] otosclerosis, 0 all others; p<0·005). The nine BPSHL patients who showed a clinical response to corticosteroids (improvement in at least one tone by audiogram or 25 db in speech discrimination score) had the highest mean antibody titre (3·46 [0·88] vs 0·59 [0·59] for the nine non-responsive patients; p<0·04). We suggest that in some patients with BPSHL, immunity to type II collagen, a major constituent of the inner ear, may be important in the pathogenesis of the disorder.

UR - http://www.scopus.com/inward/record.url?scp=0025965251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025965251&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(91)91165-Q

DO - 10.1016/0140-6736(91)91165-Q

M3 - Article

C2 - 1671423

AN - SCOPUS:0025965251

VL - 337

SP - 387

EP - 389

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8738

ER -